Stories from people navigating cholangiocarcinoma — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Oncology
The FDA approved lirafugratinib for previously treated cholangiocarcinoma with an FGFR2 fusion or other rearrangement, adding a biomarker-defined option after earlier therapy.
Dr. Abu Bakar · October 25, 2026 · 6 min
Oncology
The FDA approved lirafugratinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an eligible FGFR2 fusion or rearrangement.
Rayan Salih · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.